Next 10 |
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome PR Newswire STATEN ISLAND, N.Y. , July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:...
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "...
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference PR Newswire Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including inc...
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces the broadcasting of its national business TV show airing on Bloomberg TV as sponsored programming tonight, Thursday, June 6, 2024, at 9:30 PM PT. New to The Street's TV episode 576 will air the follo...
2024-05-15 13:14:09 ET Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Conference Call May 15, 2024, 08:00 AM ET Company Participants Robert Shawah - CFO David Luci - President and CEO Robert DeLuccia - Executive Chairman Conference Call Participants ...
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection PR Newswire Agreement with FDA reached on key elements to move forward with our international Phase 3 clinical trial program Agreement al...
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , May 15, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biophar...
2024-05-15 06:51:37 ET More on Acurx Pharmaceuticals Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Acurx Pharmaceuticals Historical earnings data for Acurx Pharmaceuticals Financial information for ...
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference PR Newswire STATEN ISLAND, N.Y. , May 2, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Compa...
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference PR Newswire STATEN ISLAND, N.Y. , April 25, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the...
News, Short Squeeze, Breakout and More Instantly...
Acurx Pharmaceuticals Inc. Company Name:
ACXP Stock Symbol:
NASDAQ Market:
Acurx Pharmaceuticals Inc. Website:
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome PR Newswire STATEN ISLAND, N.Y. , July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:...
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "...
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference PR Newswire Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including inc...